Dyadic Secures Japanese Patent for C1 Recombinant Protein Platform, Accelerates Asia-Pacific Expansion
核心洞察
The Japan Patent Office has allowed claims covering Dyadic's proprietary Thermothelomyces heterothallica (搜索) recombinant protein expression technology, strengthening its global IP portfolio.
Dyadic has engaged Intralink (搜索) to support business development in Japan, targeting partners across biopharma, food, nutrition, cosmetics, and industrial sectors.
President and COO Joe Hazelton will visit Japan in early July 2026 for meetings with high-potential existing and prospective partners.
Dyadic International (搜索), Inc. (Nasdaq: DYAI), operating as Dyadic Applied BioSolutions, announced on June 29, 2026 that the Japan Patent Office has allowed claims covering novel aspects of its proprietary Thermothelomyces heterothallica (搜索) recombinant protein expression technology. The decision marks a significant expansion of the company's intellectual property protection in one of the world's most advanced biotechnology markets.
"This patent represents an important milestone in our strategy to expand Dyadic's intellectual property position and commercial opportunities in one of the world's most advanced biotechnology markets," said Joe Hazelton, Dyadic's President and Chief Operating Officer.
The allowed claims add substantial protection to Dyadic's global IP portfolio and reinforce the strength of its differentiated C1 and Dapibus™ microbial production platforms. These platforms are engineered to enable rapid, scalable, and cost-effective production of recombinant proteins across multiple high-growth markets, including life sciences, food and nutrition, cosmetics, industrial enzymes, vaccines, monoclonal antibodies, and other biologics.
Strategic Market Expansion in Japan
Japan represents a strategic priority for Dyadic, given the country's recognized leadership in regenerative medicine, biologics manufacturing, precision fermentation, advanced bioprocessing, biopharmaceuticals, cosmetics, and food and nutrition technologies. To support its international growth strategy, Dyadic has engaged Intralink (搜索), a leading international business development and market expansion firm, to drive expansion efforts in Japan and other key markets.
These business development activities have already generated targeted engagement opportunities with prospective partners, customers, and collaborators across the biotechnology, pharmaceutical, food, nutrition, life sciences, cosmetics, and industrial sectors. Hazelton is scheduled to meet with several high-potential existing and prospective partners during a business development visit to Japan in early July 2026.
"As we continue transforming Dyadic into a recombinant protein solutions company, expanding our presence in key global biotechnology markets is an important component of our long-term growth strategy," added Hazelton. "Our collaboration with Intralink (搜索) has accelerated business development efforts in Japan and helped establish meaningful discussions with organizations seeking flexible, scalable, and cost-effective protein production solutions."
Platform Technology and Commercial Applications
Dyadic's proprietary C1 and Dapibus™ expression platforms are based on the thermophilic filamentous fungus Thermothelomyces heterothallica (搜索) and are designed to support non-animal, scalable protein production. Through commercial products, technology licensing, custom development, and strategic collaborations, the company supports customers developing applications spanning from life sciences and biopharmaceuticals to food, nutrition, and industrial enzymes.
The company believes its strengthened intellectual property portfolio, expanding commercial capabilities, growing network of strategic partners, and increasing international business development activities position it to address rising global demand for recombinant proteins and support its long-term growth strategy.